App-Quantinova.ai

The BRIGHTER trial: A phase III randomized double-blind study of BBI-608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma.

Manish A. Shah - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Paclitaxel

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high risk or node-positive prostate cancer: ENZARAD (ANZUP 1303).

Scott G. Williams - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Enzalutamide

Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304).

Ian D. Davis - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Enzalutamide

Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL MCRPC): A Movember funded multicenter, randomized, controlled phase III study.

Fred Saad - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

Avelumab (MSB0010718C; anti-PD-L1) pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer: The phase 3 JAVELIN Ovarian 200 trial.

Eric Pujade-Lauraine - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peritoneal cancer

Doxorubicin Hydrochloride

A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).

Danny Rischin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

Tarloxotinib bromide

A randomized, open-label, phase II study of CC-486 (oral azacitidine), alone or in combination with durvalumab (MEDI4736), in patients (pts) with myelodysplastic syndromes (MDS) unresponsive to prior parenteral azacitidine or decitabine.

Pierre Fenaux - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelodysplastic Syndrome

Vidaza

Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM).

Giorgio V. Scagliotti - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Malignant pleural mesothelioma

Nintedanib

A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140).

Raffit Hassan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Malignant pleural mesothelioma

anetumab ravtansine

A randomized, placebo-controlled study of amatuximab in combination with pemetrexed and cisplatin (P/C) as front-line therapy for subjects with malignant pleural mesothelioma (MPM).

Raffit Hassan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Malignant pleural mesothelioma

amatuximab

Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFRMutant, T790M-Negative NSCLC progressing on an EGFR TKI.

Stephen V. Liu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Tarloxotinib bromide

Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.

Martin Reck - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Carboplatin

A Randomized Phase 2 Study of Nivolumab and Nivolumab Combined With Ipilimumab in Patients (Pts) With Melanoma Brain Metastases: The Anti-PD1 Brain Collaboration (ABC Study).

Georgina V. Long - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Leptomeningeal Metastasis

Ipilimumab

Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022).

Georgina V. Long - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Pembrolizumab

A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265).

Georgina V. Long - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cerebral metastases

Imlygic

Defining the mechanisms of response and resistance to anti-PD-1 therapy: An exploratory phase II study of pembrolizumab in advanced melanoma (ADAPTeM).

Kroopa Joshi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Pembrolizumab

Intralesional rose bengal for treatment of melanoma.

Sanjiv S. Agarwala - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Imlygic

Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6.

Hans-Joachim Schmoll - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Capecitabine

Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML).

Courtney Denton Dinardo - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Decitabine

KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).

Johann S. De Bono - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Pembrolizumab

Filters

13968 Abstracts